Previously untargetable, the KRAS G12D mutation—often found in never-smokers—is on the verge of becoming actionable. Emerging specific inhibitors like Zoldanrasib are showing high response rates (over 60%), suggesting a new targeted therapy option for a patient group that previously lacked one.

Comprehensive molecular testing (PD-L1, EGFR, ALK) is no longer reserved for advanced disease. It is now critical for all patients with stage 1B or higher resectable NSCLC *before* starting any treatment to guide neoadjuvant and adjuvant therapy decisions.

An expert argues that existing data, based on short-term studies, grossly underappreciates the value of lung screening for SCLC. In clinical practice, robust, ongoing screening programs are diagnosing approximately 60% of SCLC cases in the limited stage, dramatically improving the potential for curative-intent therapy.

Official screening eligibility for lung cancer is narrowly focused on age and smoking history. This approach fails to account for significant environmental risk factors such as radon exposure, air pollution, and fumes from indoor cooking, leaving a large population unscreened and at risk for late-stage diagnosis.

A practical application for ctDNA is for patients with tumors not meeting strict stage criteria for adjuvant osimertinib (e.g., a T1C tumor), but who have high-risk features. A positive ctDNA result provides a compelling rationale to offer therapy in this evidence gap to target minimal residual disease.

For cancers with mutations like BRAF or MET, where both immunotherapy and targeted therapy are viable options, smoking history can guide treatment sequencing. A heavy smoking history suggests immunotherapy may be more effective upfront, whereas targeted therapy might be preferred first for non-smokers due to differences in tumor immunogenicity.

The ALENA trial, studying adjuvant alectinib for ALK-positive lung cancer, uniquely omitted platinum-based chemotherapy from its investigational arm. Its overwhelming success challenges the long-standing practice of using chemotherapy alongside targeted agents in the adjuvant setting and raises the question of whether it's necessary at all for this population.

The success of perioperative osimertinib means oncologists cannot choose the optimal strategy (targeted therapy vs. chemoimmunotherapy) for resectable lung cancer without first knowing the patient's EGFR, ALK, and PD-L1 status. This elevates biomarker profiling from a metastatic-setting tool to a critical first step in early-stage disease.

Unlike other driver mutations often associated with non-smokers, HER2 mutations in NSCLC occur equally in smokers and never-smokers, as well as across genders and ethnicities. This breaks a common clinical stereotype and underscores the necessity of universal next-generation sequencing for all patients, regardless of their profile.